[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339817-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-339817-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dosimetric-and-ntcp-analyses-for-selecting-parotid-gland-cancer-patients-for-proton-therapy","Dosimetric and NTCP analyses for selecting parotid gland cancer patients for proton therapy","","Dosimetric and normal tissue complication probability (NTCP) comparisons evaluate intensity modulated proton therapy against photon volumetric modulated arc therapy for parotid gland cancer patients in postoperative or radical settings. Thirty-seven patients treated from May 2011 to September 2021 at two institutions were included, with retrospective OAR contouring and D95 > 98% target coverage. Six NTCP models were computed via a Python script in RayStation TPS, using a two-sided Wilcoxon signed-rank test. Lower OAR Dmean values and improved NTCP profiles were observed, with roughly one-third meeting proton eligibility criteria, mainly for preventing hearing loss and tinnitus.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dosimetric-and-ntcp-analyses-for-selecting-parotid-gland-cancer-patients-for-proton-therapy/339817/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dosimetric-and-ntcp-analyses-for-selecting-parotid-gland-cancer-patients-for-proton-therapy/339817.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of the study comparing proton and photon therapy plans?","Question",{"text":63,"@type":64},"To compare dosimetric outcomes and NTCP profiles between intensity modulated proton therapy and photon volumetric modulated arc therapy for parotid gland cancer patients in postoperative or definitive settings.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients selected and how many were included?",{"text":68,"@type":64},"From May 2011 to September 2021, 37 eligible parotid gland cancer patients treated at two institutions were included based on age, appropriate radiotherapy setting, and written consent for anonymized research data.",{"name":70,"@type":61,"acceptedAnswer":71},"Which organs at risk and clinical endpoints were most affected?",{"text":72,"@type":64},"Lower mean dose to several OARs (including inner ear/cochlea and oral cavity-related structures) was found with statistically significant differences, and the largest NTCP improvements were associated with preventing hearing loss and tinnitus.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339817,1790147907,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Original Research Article  \nTj  \nTumori journal  \nDosimetric and NTCP analyses for selecting parotid gland cancer patients for proton therapy  \nTumori Journal  \n2024, Vol. 110(4) 273–283 © Fondazione IRCCS Istituto Nazionale dei Tumori 2024  \nArticle reuse guidelines: [sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/03008916241252544](DOI: 10.1177/03008916241252544)[ ](DOI: 10.1177/03008916241252544)[journals.sagepub.com/home/tmj](journals.sagepub.com/home/tmj)  \nAnna Maria Camarda 1,2,3\\#, Maria Giulia Vincini2, Stefania Russo4, Stefania Comi5, Francesca Emiro5, Alessia Bazani4, Rossana Ingargiola 1, Barbara Vischioni 1, Claudio Vecchi6, Stefania Volpe2,3, Roberto Orecchia7, Barbara Alicja Jereczek-Fossa2,3, Ester Orlandi 1,8†  \nand Daniela Alterio2†  \nAbstract  \nPurpose/Objective: To perform a dosimetric and a normal tissue complication probability (NTCP) comparison between intensity modulated proton therapy and photon volumetric modulated arc therapy in a cohort of patients with parotid gland cancers in a post-operative or radical setting.  \nMaterials and methods: From May 2011 to September 2021, 37 parotid gland cancers patients treated at two institutions were eligible. Inclusion criteria were as follows: patients aged ⩾ 18 years, diagnosis of parotid gland cancers candidate for postoperative radiotherapy or definitive radiotherapy, presence of written informed consent for the use of anonymous data for research purposes. Organs at risk (OARs) were retrospectively contoured. Target coverage goal was defined as D95 > 98%. Six NTCP models were selected. NTCP profiles were calculated for each patient using an internally-developed Python script in RayStation TPS. Average differences in NTCP between photon and proton plans were tested for significance with a two-sided Wilcoxon signed-rank test.  \nResults: Seventy-four plans were generated. A lower Dmean to the majority of organs at risk (inner ear, cochlea, oral cavity, pharyngeal constrictor muscles, contralateral parotid and submandibular gland) was obtained with intensity modulated proton therapy vs volumetric modulated arc therapy with statistical significance (p \u003C .05). Ten (27%) patients had a difference in NTCP (photon vs proton plans) greater than 10% for hearing loss and tinnitus: among them, seven qualified for both endpoints, two patients for hearing loss only, and one for tinnitus.  \nConclusions: In the current study, nearly one-third of patients resulted eligible for proton therapy and they were the most likely to benefit in terms of prevention of hearing loss and tinnitus.  \nKeywords  \nNTCP models, parotid gland cancer, intensity modulated proton therapy, patient selection  \nDate received: 17 August 2023; revised: 25 March 2024; accepted: 17 April 2024  \n1 Radiation Oncology Unit, Clinical Department, National Center for Oncological Hadrontherapy, Pavia, Italy  \n2Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy  \n3Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy  \n4Medical Physics Unit, Clinical Department, National Center for Oncological Hadrontherapy, Pavia, Italy  \n5Unit of Medical Physics, European Institute of Oncology IRCCS, Milan, Italy  \n6Tecnologie Avanzate Srl, Turin, Italy  \n7Scientific Directorate, European Institute of Oncology IRCCS, Milan, Italy  \n8Department of Clinical, Surgical, Diagnostic and Pediatric Sciences,University of Pavia, Italy  \n†Daniela Alterio and Ester Orlandi are co-last authors  \n\\#affiliation at the time of the study  \nCorresponding author:  \nMaria Giulia Vincini, Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Via Ripamonti, 435, Milan, 20141, Italy. [Email: mariagiulia.vincini@ieo.it](Email: mariagiulia.vincini@ieo.it)  \nIntroduction  \nSalivary gland cancers (SGCs) represent a rare disease, accounting for approximately 2-6.5 % of all head and neck cancers (HNCs) .1 P","cbCaiuHnqsmtmXFB","https://ap.wps.com/l/cbCaiuHnqsmtmXFB","pdf",621285,11,"English","# Materials and methods\n## Patient cohort and inclusion criteria\n## Treatment planning and target coverage\n## NTCP model selection and calculation\n# Results\n## Plan generation and dosimetric/NTCP differences\n## Patients meeting proton eligibility thresholds\n# Conclusions\n## Clinical relevance for hearing outcomes","[{\"question\":\"What was the purpose of the study comparing proton and photon therapy plans?\",\"answer\":\"To compare dosimetric outcomes and NTCP profiles between intensity modulated proton therapy and photon volumetric modulated arc therapy for parotid gland cancer patients in postoperative or definitive settings.\"},{\"question\":\"How were patients selected and how many were included?\",\"answer\":\"From May 2011 to September 2021, 37 eligible parotid gland cancer patients treated at two institutions were included based on age, appropriate radiotherapy setting, and written consent for anonymized research data.\"},{\"question\":\"Which organs at risk and clinical endpoints were most affected?\",\"answer\":\"Lower mean dose to several OARs (including inner ear/cochlea and oral cavity-related structures) was found with statistically significant differences, and the largest NTCP improvements were associated with preventing hearing loss and tinnitus.\"}]","Dosimetric and NTCP analyses for selecting parotid gland cancer patients for proton therapy | PDF",1790032431,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b1cfa51d5ad0384ba6c2f20f6493a304.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ee0b5133cec88777dfbf086822eb058.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d07c1d11c31d48e72171db09d483789.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12b5a6d4cd3b3149809ad4e33cf00ace.webp",980,1306]